{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:58:38Z","timestamp":1788238718448,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":1014,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim was to describe the prevalence, characteristics, and outcome of patients with acute myocardial infarction (MI) developing left ventricular (LV) systolic dysfunction or pulmonary congestion by applying different criteria to define the population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In patients with MI included in the Swedish web-system for enhancement and development of evidence-based care in heart disease (SWEDEHEART) registry, four different sets of criteria were applied, creating four not mutually exclusive subsets of patients: patients with MI and ejection fraction (EF) &amp;lt; 50% and\/or pulmonary congestion (subset 1); EF &amp;lt; 40% and\/or pulmonary congestion (subset 2); EF &amp;lt; 40% and\/or pulmonary congestion and at least one high-risk feature (subset 3, PARADISE-MI like); and EF &amp;lt; 50% and no diabetes mellitus (subset 4, DAPA-MI like). Subsets 1, 2, 3, and 4 constituted 31.6%, 15.0%, 12.8%, and 22.8% of all patients with MI (n = 87 177), respectively. The age and prevalence of different co-morbidities varied between subsets. For median age, 70 to 77, for diabetes mellitus, 22 to 33%; for chronic kidney disease, 22 to 38%, for prior MI, 17 to 21%, for atrial fibrillation, 7 to 14%, and for ST-elevations, 38 to 50%. The cumulative incidence of death or heart failure hospitalization at 3 years was 17.4% (95% CI: 17.1\u201317.7%) in all MIs; 26.9% (26.3\u201327.4%) in subset 1; 37.6% (36.7\u201338.5%) in subset 2; 41.8% (40.7\u201342.8%) in subset 3; and 22.6% (22.0\u201323.2%) in subset 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Depending on the definition, LV systolic dysfunction or pulmonary congestion is present in 13\u201332% of all patients with MI and is associated with a two to three times higher risk of subsequent death or HF admission. There is a need to optimize management and improve outcomes for this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14301","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:33:48Z","timestamp":1675384428000},"page":"1347-1357","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Prevalence and Prognostic Impact of Left Ventricular Systolic Dysfunction or Pulmonary Congestion After Acute Myocardial Infarction"],"prefix":"10.1093","volume":"10","author":[{"given":"Eleonora","family":"Hamilton","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyew","family":"Desta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Novartis , T\u00e4by ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Alfredsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Department of Health, Medicine and Caring Sciences, Link\u00f6ping University , Link\u00f6ping ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Christersson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Department of Cardiology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Department of Clinical Sciences, Lund University, Skane University Hospital , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kellerth","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Lindmark","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Heart Centre, Department of Public Health and Clinical Medicine, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmir","family":"Omerovic","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sahlgrenska University Hospital Institute of Medicine, Department of Molecular and Clinical Medicine, Academy at University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reitan","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"2026012114120288600_ehf214301-bib-0001","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2011.522","article-title":"Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction","volume":"305","author":"Jernberg","year":"2011","journal-title":"JAMA"},{"key":"2026012114120288600_ehf214301-bib-0002","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/eurheartj\/ehi352","article-title":"Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014","volume":"26","author":"Szummer","journal-title":"Eur Heart J"},{"key":"2026012114120288600_ehf214301-bib-0003","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1093\/eurheartj\/ehy554","article-title":"Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014","volume":"39","author":"Szummer","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114120288600_ehf214301-bib-0004","first-page":"234","article-title":"Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART registry (Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008","volume":"3","author":"Desta","year":"2015","journal-title":"JACC: Heart Fail"},{"key":"2026012114120288600_ehf214301-bib-0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ejhf.416","article-title":"Heart failure with normal ejection fraction is uncommon in acute myocardial infarction settings but associated with poor outcomes: a study of 91 360 patients admitted with index myocardial infarction between 1998 and 2010","volume":"18","author":"Desta","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114120288600_ehf214301-bib-0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijcard.2017.05.086","article-title":"Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: a Swedish nationwide observational study","volume":"248","author":"Desta","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026012114120288600_ehf214301-bib-0007","volume-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure"},{"key":"2026012114120288600_ehf214301-bib-0008","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114120288600_ehf214301-bib-0009","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline characteristics","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114120288600_ehf214301-bib-0010","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","article-title":"The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)","volume":"96","author":"Jernberg","year":"2010","journal-title":"Heart"},{"key":"2026012114120288600_ehf214301-bib-0011","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(13)62070-X","article-title":"Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK","volume":"383","author":"Chung","year":"2014","journal-title":"The Lancet"},{"key":"2026012114120288600_ehf214301-bib-0012","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijcard.2014.04.270","article-title":"International comparisons of the management of patients with non-ST segment elevation acute myocardial infarction in the United Kingdom, Sweden, and the United States: the MINAP\/NICOR, SWEDEHEART\/RIKS-HIA, and ACTION registry-GWTG\/NCDR registries","volume":"175","author":"McNamara","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026012114120288600_ehf214301-bib-0013","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/ehjqcco\/qcw004","article-title":"Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors ofmyocardial infarction","volume":"2","author":"Rapsomaniki","year":"2016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026012114120288600_ehf214301-bib-0014","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ehjqcco\/qcaa098","article-title":"Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries","volume":"8","author":"Bl\u00f6ndal","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026012114120288600_ehf214301-bib-0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ehjqcco\/qcab013","article-title":"Differences in characteristics, treatments and outcomes in patients with non-ST-elevation myocardial infarction: novel insights from four national European continuous real-world registries","volume":"8","author":"Edfors","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026012114120288600_ehf214301-bib-0016","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline characteristics methods and results","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114120288600_ehf214301-bib-0017","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"2026012114120288600_ehf214301-bib-0018","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (TRACE) study group {see comments}","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"2026012114120288600_ehf214301-bib-0019","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2026012114120288600_ehf214301-bib-0020","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026012114120288600_ehf214301-bib-0021","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"The Lancet"},{"key":"2026012114120288600_ehf214301-bib-0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Different perspectives on outcomes in patients with non-ST-elevation myocardial infarction when observed in clinical trials and in real life","volume":"29","author":"Wallentin","journal-title":"Eur Heart J"},{"key":"2026012114120288600_ehf214301-bib-0023","article-title":"Heart failure after ST-elevation myocardial infarction: beyond left ventricular adverse remodeling","author":"del Buono","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2026012114120288600_ehf214301-bib-0024","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14301","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/2\/1347\/65051578\/eschf_10_2_1347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/2\/1347\/65051578\/eschf_10_2_1347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:13:25Z","timestamp":1769022805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/2\/1347\/8304926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,2]]},"published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14301","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"2022-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}